{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-042118","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.865020+00:00","generated_at":"2026-05-16T19:42:00.648973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin reports Q3 net loss of $0.13/sh; cash $11.5M; NAVIGATE data submitted to FDA","bullets":["Net loss of $8.2M ($0.13/share) vs $11.2M ($0.18/share) in Q3 2024; R&D spend down to $2.6M as NAVIGATE trial ended.","Cash and equivalents $11.5M at Sep 30; plus $10M line of credit from chairman; runway through June 2026.","New 18-month NAVIGATE biomarker data showed belapectin reduced portal hypertension risk categories vs placebo.","FDA data package submitted for belapectin in MASH cirrhosis; agency feedback expected by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-042118","json":"https://secwatch.observer/filing/0001140361-25-042118.json","markdown":"https://secwatch.observer/filing/0001140361-25-042118.md","text":"https://secwatch.observer/filing/0001140361-25-042118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/0001140361-25-042118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036125042118/ny20058903x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:42:00.648973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}